222 related articles for article (PubMed ID: 21485840)
1. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer.
Aggarwal S; Yadav S; Gupta S
J Biomed Nanotechnol; 2011 Feb; 7(1):137-8. PubMed ID: 21485840
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy.
Jaidev LR; Krishnan UM; Sethuraman S
Mater Sci Eng C Mater Biol Appl; 2015 Feb; 47():40-7. PubMed ID: 25492170
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies.
Jamil A; Aamir Mirza M; Anwer MK; Thakur PS; Alshahrani SM; Alshetaili AS; Telegaonkar S; Panda AK; Iqbal Z
Drug Dev Ind Pharm; 2019 May; 45(5):745-753. PubMed ID: 30632800
[TBL] [Abstract][Full Text] [Related]
5. Multi-functional nanoparticles as theranostic agents for the treatment & imaging of pancreatic cancer.
Jaidev LR; Chellappan DR; Bhavsar DV; Ranganathan R; Sivanantham B; Subramanian A; Sharma U; Jagannathan NR; Krishnan UM; Sethuraman S
Acta Biomater; 2017 Feb; 49():422-433. PubMed ID: 27890622
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate.
Khare V; Kour S; Alam N; Dubey RD; Saneja A; Koul M; Gupta AP; Singh D; Singh SK; Saxena AK; Gupta PN
Int J Pharm; 2014 Aug; 470(1-2):51-62. PubMed ID: 24810239
[TBL] [Abstract][Full Text] [Related]
7. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
8. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
Mondal G; Almawash S; Chaudhary AK; Mahato RI
Mol Pharm; 2017 Sep; 14(9):3121-3133. PubMed ID: 28719220
[TBL] [Abstract][Full Text] [Related]
9. Synergistic targeting/prodrug strategies for intravesical drug delivery--lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer.
Neutsch L; Wirth EM; Spijker S; Pichl C; Kählig H; Gabor F; Wirth M
J Control Release; 2013 Jul; 169(1-2):62-72. PubMed ID: 23588390
[TBL] [Abstract][Full Text] [Related]
10. Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing for efficient antitumor activity.
Martín-Banderas L; Sáez-Fernández E; Holgado MÁ; Durán-Lobato MM; Prados JC; Melguizo C; Arias JL
Int J Pharm; 2013 Feb; 443(1-2):103-9. PubMed ID: 23299085
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells.
Papa AL; Basu S; Sengupta P; Banerjee D; Sengupta S; Harfouche R
BMC Cancer; 2012 Sep; 12():419. PubMed ID: 22998550
[TBL] [Abstract][Full Text] [Related]
12. BSA-PLGA-based core-shell nanoparticles as carrier system for water-soluble drugs.
Chitkara D; Kumar N
Pharm Res; 2013 Sep; 30(9):2396-409. PubMed ID: 23756758
[TBL] [Abstract][Full Text] [Related]
13. Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery.
Joshi G; Kumar A; Sawant K
Eur J Pharm Sci; 2014 Aug; 60():80-9. PubMed ID: 24810394
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs) using central composite design.
Yalcin TE; Ilbasmis-Tamer S; Takka S
Int J Pharm; 2018 Sep; 548(1):255-262. PubMed ID: 29969712
[TBL] [Abstract][Full Text] [Related]
15. UPEC biomimickry at the urothelial barrier: lectin-functionalized PLGA microparticles for improved intravesical chemotherapy.
Neutsch L; Wambacher M; Wirth EM; Spijker S; Kählig H; Wirth M; Gabor F
Int J Pharm; 2013 Jun; 450(1-2):163-76. PubMed ID: 23628404
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of biodegradable polymeric nanoparticles and their controlled drug delivery for tuberculosis.
Malathi S; Balasubramanian S
J Biomed Nanotechnol; 2011 Feb; 7(1):150-1. PubMed ID: 21485846
[TBL] [Abstract][Full Text] [Related]
17. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
[TBL] [Abstract][Full Text] [Related]
18. Development of Gemcitabine Loaded PLGA/Lecithin Nanoparticles for Non-Small Cell Lung Cancer Therapy.
Esim O; Ozkan CK; Sarper M; Savaser A; Ozkan Y
Curr Drug Deliv; 2020; 17(7):622-628. PubMed ID: 32394837
[TBL] [Abstract][Full Text] [Related]
19. Thyrotropin-Releasing Hormone Loaded and Chitosan Engineered Polymeric Nanoparticles: Towards Effective Delivery of Neuropeptides.
Kaur S; Bhararia A; Sharma K; Mittal S; Jain R; Wangoo N; Sharma RK
J Nanosci Nanotechnol; 2016 May; 16(5):5324-32. PubMed ID: 27483926
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
Patra CR; Bhattacharya R; Wang E; Katarya A; Lau JS; Dutta S; Muders M; Wang S; Buhrow SA; Safgren SL; Yaszemski MJ; Reid JM; Ames MM; Mukherjee P; Mukhopadhyay D
Cancer Res; 2008 Mar; 68(6):1970-8. PubMed ID: 18339879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
